moneyheap
XERS · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Xeris Biopharma Holdings, Inc. Common Stock (XERS) stock moving?
XERS jumped on its Q3 2026 report on Nov 5: revenue rose 44% year over year to $107M, adjusted EPS of $0.06 beat the $0.02 estimate, and FY2026 sales guidance was raised to $395M-$405M from $385M-$390M, above the $387.7M consensus. The company also now targets FY2030 revenue above $1B, up from $750M. The stock closed at $10.46 on Nov 4 and $15.83 on Nov 10, about 51% higher, with most of the gain on Nov 5 (+25%, 12.6M shares versus roughly 1.5M to 2.4M a day in the prior weeks) and Nov 6 (+16%, close $15.20). After the Nov 6 rally, three analysts raised targets: Oppenheimer to $21 (Outperform), HC Wainwright to $18 (Buy), and Piper Sandler to $12 (Neutral), the last below the current price. Volume has since faded to 3.8M on Nov 10 from 12.6M, and the stock is holding near $15.2 to $16.1, with the Nov 10 high at $16.11. A $312K insider sale was reported Nov 8, and a new director joined the board Nov 2. The earnings beat-and-raise is a concrete, recent catalyst, but the price has already moved sharply and sits above two of three new targets. The pending FY2030 target and the Oct 13 patent suits against generic dichlorphenamide makers depend on future execution.
News behind the analysis
- Xeris Biopharma Holdings Q3 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $106.267M Beat $101.517M EstimateThird-quarter adjusted EPS of $0.06 beat the $0.02 estimate, and sales of $106.267M beat the $101.517M estimate.
- Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business HighlightsXeris reported a 44% year-over-year revenue increase to $107 million and raised its full-year 2026 and 2030 revenue outlooks.
- Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $385.000M-$390.000M to $395.000M-$405.000M vs $387.665M EstFull-year 2026 sales guidance was raised to $395M-$405M, above the $387.665M consensus estimate.
- Xeris Biopharma Holdings FY2030 Revenue expected to be more than 1 Billion up from $750MThe company now expects FY2030 revenue above $1 billion, up from a prior $750M outlook.
- Oppenheimer Adjusts Xeris Biopharma PT to $21 From $18, Maintains Outperform RatingOppenheimer raised its price target to $21 from $18 and kept an Outperform rating.
- Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21Oppenheimer reiterated its Outperform rating and raised its price target to $21.
- HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18HC Wainwright kept its Buy rating and raised its price target to $18.
- Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12Piper Sandler kept a Neutral rating and raised its price target to $12, below the latest close of $15.83.
- Xeris Biopharma Insider Sells Shares Worth $312,215An insider sold shares valued at $312,215, according to a recent SEC filing.
- Xeris Biopharma Appoints Menassie M. Taddese to Board of DirectorsMenassie M. Taddese joined the Board of Directors effective November 2, 2026, and was appointed to the Audit Committee.
About Xeris Biopharma Holdings, Inc. Common Stock
Xeris Biopharma is a Chicago-based drug company that sells medicines for endocrine (hormone-related) and rare diseases, including Recorlev for Cushing's syndrome, Gvoke ready-to-use glucagon for severe low blood sugar, and Keveyis for primary periodic paralysis. What sets it apart is its XeriSol and XeriJect technology for making stable, ready-to-inject drug formulations, plus fast growth driven by Recorlev. In the third quarter of 2026, total revenue rose about 44% from a year earlier to roughly $107 million.
How it makes money
Nearly all of its revenue comes from selling its three marketed drugs in the US. Recorlev is now the largest, at roughly two-thirds of product revenue (about $71 million in Q3 2026). Gvoke and Keveyis make up most of the rest. A small amount comes from licensing and partnership deals that use its formulation technology. The company expects roughly $395–405 million in total revenue for 2026 and has set a goal of more than $1 billion by 2030. It is still investing in development, including XP-8121, a once-weekly injectable treatment for hypothyroidism that is heading into Phase 3 trials.
What usually moves XERS
- Recorlev prescription growth and new patient starts
- Quarterly results versus revenue guidance
- XP-8121 Phase 3 trial progress
- Patent protection and litigation over Recorlev
- Profitability and cash flow trends